Objective-The newly identified apolipoprotein A5 (APOA5), selectively expressed in the liver, is a crucial determinant of plasma triglyceride levels. Because elevated plasma triglyceride concentrations constitute an independent risk factor for cardiovascular diseases, it is important to understand how the expression of this gene is regulated. In the present study, we identified the retinoic acid receptor-related orphan receptor-␣ (ROR␣) as a regulator of human APOA5 gene expression. Methods and Results-Using electromobility shift assays, we first demonstrated that ROR␣1 and ROR␣4 proteins can bind specifically to a direct repeat 1 site present at the position Ϫ272/Ϫ260 in the APOA5 gene promoter. Key Words: apolipoprotein A5 Ⅲ nuclear receptor ROR␣ Ⅲ triglyceride homeostasis Ⅲ transcriptional regulation C ardiovascular diseases are a major cause of death in the world. 1,2 Several epidemiological studies have established that in addition to elevated low-density lipoprotein and reduced high-density lipoprotein levels, elevated blood triglyceride level is an independent risk factor for coronary heart disease. 3,4 Therefore, the identification of factors or genes capable of affecting triglyceride homeostasis is of major medical importance for the treatment of hypertriglyceridemia and associated coronary heart disease.
C ardiovascular diseases are a major cause of death in the world. 1, 2 Several epidemiological studies have established that in addition to elevated low-density lipoprotein and reduced high-density lipoprotein levels, elevated blood triglyceride level is an independent risk factor for coronary heart disease. 3, 4 Therefore, the identification of factors or genes capable of affecting triglyceride homeostasis is of major medical importance for the treatment of hypertriglyceridemia and associated coronary heart disease.
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The newly identified apolipoprotein A5 (APOA5) is located proximal to the well-characterized APOA1/C3/A4 gene cluster on human 11q23. Predominantly expressed in the liver, the apolipoprotein A5 is an important determinant of plasma triglyceride levels both in humans and mice 5 and is associated with an early phase of liver regeneration. 6 To study the function of APOA5 on triglyceride homeostasis, human APOA5 transgenic and knockout mice were generated. 5 Transgenic mice exhibited markedly decreased levels of plasma triglyceride that were approximately one-third of those of control mice, whereas knockout mice had Ϸ4-fold increased plasma triglycerides compared with wild-type mice. In a previous study, we investigated the mechanism by which apolipoprotein (apoA-V) affects lipid metabolism in transgenic mice overexpressing hAPOA5 gene. 7 We found that apoA-V does not affect very-low-density lipoprotein (VLDL) triglyceride synthesis and secretion but accelerates VLDL catabolism by activating lipolysis and enhancing VLDL removal from the plasma. 7 Taken together, these findings demonstrate that APOA5 regulates plasma triglyceride level only by increasing triglyceride catabolism in vivo. In addition, several DNA sequence polymorphisms in the gene have been found to be linked to increased plasma triglyceride levels, 8 and subsequently to an increased risk of myocardial infarction. 9 These data suggest that APOA5 could be a strong modulator of triglyceride levels. Therefore, studying factors that regulate its expression is of significant clinical importance for the treatment of dyslipidemia.
It was previously described that APOA5 gene expression is increased by peroxisome proliferator-activated receptor-␣/ retinoid X receptor dimers that bind to a direct repeat 1 (DR1) sequence located at the position Ϫ272/Ϫ260 in the APOA5 gene promoter. 10, 11 Recently, SREBP1c has been reported to downregulate APOA5 gene expression via a direct binding to the functional E-box present in human APOA5 promoter. 12 The retinoic acid receptor-related orphan receptors (RORs) constitute a subfamily of orphan receptors encoded by 3 different genes, ROR␣, ROR␤, and ROR␥. [13] [14] [15] RORs were initially reported to bind to response elements (retinoic acid receptor-related orphan receptor response element [RORE] ) consisting of a 6-bp A/T-rich sequence preceding the halfcore PuGGTCA motif. [15] [16] [17] However, more complex RORE have also been described such as direct repeats of the PuGGTCA motifs preceded by a 6-bp A/T-rich sequence. 18 Because of alternative splicing and promoter usage, the ROR␣ gene gives rise to 4 isoforms: ␣1, ␣2, ␣3, and ␣4 (or RZRa), 14, 15, 19 which differ in their N-terminal domains and display distinct DNA recognition and transactivation properties. 15 In contrast to ROR␤, only expressed in brain, retina, and pineal gland, 20 both ROR␣ and ROR␥ are widely expressed in peripheral tissues. 13, 15, 16, 19 Staggerer mice (sg/ sg) carry a natural deletion in the ROR␣ gene that prevents the translation of its putative ligand-binding domain, thereby presumably disrupting the normal function of this transcription factor. 21 Interestingly, in addition to severe neurological disorders, 22 these mice display metabolic abnormalities. [23] [24] [25] These mice, maintained on an atherogenic diet, have severe hypoalphalipoproteinemia and atherosclerosis. 25 Furthermore, ROR␣ has already been involved in apolipoprotein A1 and C3 gene transcriptional regulation. 23, 24 These data suggest an important role for ROR␣ in lipoprotein metabolism and cardiovascular diseases.
In the present study, we demonstrated that both ROR␣1 and ROR␣4 isoforms are positive regulators of human APOA5 gene transcription. Our data identify APOA5 as a new target gene for ROR␣ and suggest a role for ROR␣ in plasma triglyceride homeostasis.
Methods

Cloning and Construction of Recombinant Plasmids
The human APOA5 promoter fragment (Ϫ305/ϩ62) was amplified by polymerase chain reaction (PCR) using an APOA5 genomic BAC clone 5, 10 as template and cloned in the pGL3 luciferase vector. The forward oligonucleotide 5Ј-TCTGTTGGGGCCAGCCAG-3Ј and reverse oligonucleotide 5Ј-AATGCCCTCCCTTAGGACTGTGAC-3Ј primers were used for the PCR reaction. Site-directed mutagenesis of the construct (Ϫ305/ϩ62) (Ϫ270 G3 C , Ϫ263 G3 A ) was accomplished using the QuikChange site-directed mutagenesis kit (Stratagene) according to the recommendations of the manufacturer with the following oligonucleotides: forward 5Ј-AGTGGGAAGCTTAA-AGATCATGGGGTT-3Ј and reverse 5Ј-AACCCCATGATCTTTA-AGCTTCCCACT-3Ј. The human wild-type APOA5-DR1 (Ϫ284/-243) (5Ј-AGGTCAGTGGGAAGGTTAAAGGTCATGGGGTTTGGGAG-AAAC-3Ј) oligonucleotide was cloned in 4 copies into the SV40-pGL3. The pCDNA3-hROR expression vectors have been previously described. 26 The constructs Ad-GFP and Ad-ROR␣1, as well as the corresponding adenoviral particles, were prepared as described previously. 26 pAd-ROR␣4 and pAd-LacZ adenovirus were obtained by the Vira Power Adenoviral Expression system (Invitrogen, Paislay, UK). Briefly, ROR␣4 and control LacZ cDNA were cloned in pAd DEST-based expression vector (Bett et al, 1994); 293 A cells were transfected with pAd vectors to produce an adenoviral stock. This stock was amplified, purified on cesium chloride, and titered by a plaque assay in 96-well plates to define the titer in pfu/mL.
Cell Culture, Viral Infection, and Transient Transfection Assays
Human hepatoma HepG2 and HuH7 cells were obtained from the European Collection of Animal Cell Culture (Porton Down, Salisbury, UK). Cell lines were maintained in standard culture conditions (Dulbecco's modified Eagle's minimal essential medium) supplemented with 10% fetal calf serum, 5% nonessential amino acids, and 5% sodium pyruvate (Invitrogen) at 37°C CO 2 , 95% air. Medium was changed every 2 days.
For adenovirus experiments, HepG2 cells were seeded in 6-well plates at a density of 5ϫ10 5 cells/well and incubated at 37°C before viral infection. Viral particles were added at a multiplicity of infection of 100 and incubated for 3 hours. HepG2 cells were infected with adenovirus coding, respectively, for ROR␣1 or ROR␣4 (Ad-ROR␣1, Ad-ROR␣4) or with control adenovirus coding for GFP (Ad-GFP, green fluorescent protein) or LacZ (Ad-LacZ, ␤-galactosidase). Thereafter, cells were washed with phosphatebuffered saline and incubated in culture medium for the indicated times. At the end of the experiment, cells were washed once with ice-cold phosphate-buffered saline, lysed, and scraped in 0.5 mL of ice-cold Trizol reagent.
For transfection experiments, HepG2 and HuH7 cells were seeded in 24-well plates at a density of 10 5 cells per well and incubated at 37°C for 16 hours before transfection. Cells were transfected by the calcium phosphate coprecipitation procedure using 300 ng of reporter vector and different quantities (10, 30, 100, and 300 ng) of pCDNA3-hROR␣1, ␣2, ␣3, ␣4, and ␥ expression vectors, or empty pCDNA3 plasmid vector as control. The total amount of DNA was kept constant by complementation with pCDNA3 empty vector. At the end of the experiment, the cells were washed with ice-cold phosphate-buffered saline, and the luciferase activity was measured using a luciferase assay system (Promega Corp, Madison, Wis).
Mice
Staggerer mutant mice were obtained by crossing heterozygote (ϩ/sg) mice maintained in a C57BL/6 genetic background and maintained on chow diet as previously described. 24 Wild-type littermates of the same age as the homozygous mutants were used as control.
Gel Retardation Assays
The pCDNA3-hROR␣1, ␣2, ␣3, ␣4, and ␥ expression plasmids were transcribed in vitro using T7 polymerase and subsequently translated using rabbit reticulocyte lysate as recommended by the manufacturer (Promega). DNA protein-binding assays were conducted as described 27 using the following binding buffer:
and herring sperm DNA 50 ng/L containing 3 L of programmed or unprogrammed reticulocyte lysate. Double-stranded oligonucleotides corresponding to the wild-type (forward 5Ј-GGGAAGGTTAAAGGTCATGGG-3Ј and reverse 5Ј-CCCATGACCTTTAACCTTCCC-3Ј) or mutated (forward 5Ј-AGTGGGAAGCTTAAAGATCATGGGGTT-3Ј and reverse 5Ј-AACCCCATGATCTTTAAGCTTCCCACT-3Ј) hAPOA5-DR1 response element present in the hAPOA5 promoter and oligonucleotides corresponding to the wild-type mapoa5 sequence (forward 5Ј-GGGGCGGTTGCTGGTCACAGGA-3Ј and reverse 5Ј-TCCTG-TGACCAGCAACCGCCCC-3Ј) were radiolabeled [␥-32P]ATP using T4 polynucleotide kinase and used as probes. For competition experiments, 25-, 100-, 200-, and 400-fold excess of cold wild-type or mutated probe was included 20 minutes before adding labeled probe. For supershift assays, 5 L of 1X polyclonal ROR␣ antibody (Santa Cruz Biotechnology, Le Perray en Yvelines, France) were added to the binding reaction. DNA-binding complexes were resolved by 5% native polyacrylamide gel electrophoresis (PAGE) in 0.25X TBE. Gels were dried and exposed at Ϫ80°C to XOMAT-AR film (Eastman Kodak Co, Rochester, New York).
RNA Analysis Experiments
Total RNA extraction was performed with Trizol reagent (Invitrogen) as indicated by the manufacturer. RNA expression of human and mouse apolipoprotein A5 and 36B4 genes was analyzed by real-time quantitative PCR using SYBR Green technology on a MX4000 apparatus (Stratagene Europe, Amsterdam, the Nederlands). PCR was performed with oligonucleotides forward 5Ј-ACGCACGCATCCAGCAGAAC-3Ј and reverse 5Ј-TCGGA-GAGCATCTGGGGGTC-3Ј for human APOA5, forward 5Ј-CTC-TGTCCCACAAACTCACACG 3Ј and reverse 5Ј-AGGTAGGT-GTCATGCCGAAAAG-3Ј for mouse apoa5, and forward 5Ј-CATGCTCAACATCTCCCCCTTCTCC-3Ј and reverse 5Ј-GG-GAAGGTGTAATCCGTCTCCACAG-3Ј for 36B4. Quantification of APOA5 and apoa5 mRNA levels was normalized using 36B4 as housekeeping gene.
Statistical Analysis
Results are presented as mean Ϯ SD. Statistical analysis was performed using t tests and PϽ0.05 was considered statistically significant.
Results
ROR␣1 and ROR␣4 Proteins Specifically Bind to a DR1 Site in the Human APOA5 Gene Promoter
It was previously described that peroxisome proliferator-activated receptor-␣/retinoid X receptor dimers bind to a DR1 site present at the position Ϫ272/Ϫ260 in the human APOA5 gene promoter. 10, 11 Because this site presents structural homologies with the binding site for the orphan nuclear receptor hROR␣, we evaluated whether hROR proteins translated in vitro could bind to this site by electromobility shift assay. As shown in Figure 1A , only in vitro translated hROR␣1 and ROR␣4 proteins bound to the DR1 site, whereas ROR␣2, ␣3, and ␥ failed to bind this site (a SDS-PAGE analysis was performed with the translated products in the presence of 35S methionine and demonstrated that all the ROR isoforms, ␣1,␣2, ␣3, ␣4, and ␥, are synthesized in equivalent amounts [data not shown]). The specificity of both hROR␣1 and ROR␣4 protein bindings to the hAPOA5 promoter ROR response element-direct repeat 1 (RORE-DR1), was determined first by using a specific antibody against ROR␣, which results in a supershift of the binding for ROR␣1 and in an inhibition of the binding for ROR␣4 ( Figure 1A) . Next, the mutated (Ϫ270 G3 C , Ϫ263 G3 A ) radiolabeled DR1 site probe in electromobility shift assay failed to bind both ROR␣1 and ROR␣4 ( Figure 1A ). Furthermore, a competition with unlabeled wild-type RORE-DR1 site resulted in a complete inhibition of the binding. However, the unlabeled mutated RORE-DR1 ( Figure 1B ) failed to compete with the binding of both ROR␣1 and ROR␣4 proteins to the RORE-DR1 site. These data indicate that the RORE-DR1 site present in the human APOA5 gene promoter is a binding site for both ROR␣1 and ROR␣4 nuclear receptors.
Using a labeled consensus probe that binds in vitro monomers and dimers as reference, we determined that ROR␣1 and ROR␣4 bind as monomers to hAPOA5 RORE-DR1 (data not shown). Interestingly, hROR␣1 and hROR␣4 proteins, which are the only isoforms expressed in the liver, 28 can bind to the identified RORE, whereas hROR␣2, hROR␣3, and hROR␥ proteins cannot bind to this response element ( Figure 1A) .
To determine whether this binding could be extended to mice, the mouse homologous region was tested in an electromobility shift assay with in vitro translated ROR proteins. No binding was observed with the mouse site (Figure 2A ). In addition, the comparison of the identified human APOA5 RORE-DR1 with the homologous region of other species showed that this site is conserved only in chimpanzee and baboon sequences ( Figure 2B ). In mouse, the homologous site deviates from the core motif by 1 nucleotide, and this divergence could explain the lack of binding in gel shift assay.
ROR␣1 and ROR␣4 Enhance the Activity of the Human APOA5 Gene Promoter
Next, we investigated whether ROR␣1, ␣2, ␣3, ␣4, and ␥ can modulate APOA5 gene promoter transcriptional activity. HepG2 and HuH7 human hepatocytes were transiently co- transfected with a luciferase reporter vector driven by the human promoter fragment (Ϫ305/ϩ62) ( Figure 3A ) and the different isoforms of ROR. The results in Figure 3B (HepG2 cells) and 3C (HuH7 cells) show that only ROR␣1 and ROR␣4 increased human APOA5 promoter activity, whereas ROR␣2, ␣3, and ␥ had no effect. These data are in agreement with the gel shift assay findings and confirm that only ROR␣1 and ROR␣4 are functional. Then, we showed that the transcriptional activity of the APOA5 reporter construct was strongly increased in a dose-dependent manner by the cotransfection of either ROR␣1 or ROR␣4 expression vectors in HepG2 cells ( Figure 3D ) and in HuH7 cells ( Figure 3E ). To demonstrate that the increase of human promoter activity by ROR␣1 and ROR␣4 is caused by their binding to the identified RORE-DR1 at the position Ϫ272/Ϫ260, HepG2 and HuH7 cells were transiently transfected with the luciferase reporter vector driven by the mutated human APOA5 promoter fragment Ϫ305/ϩ62 (Ϫ270 G3 C , Ϫ263 G3 A ). The response of the mutated construct to ROR␣1 or ROR␣4 was strongly decreased compared with the wild-type construct in Figure 2 . ROR␣ proteins do not bind to the mouse promoter homologous sequence. A, A gel retardation assay was performed with the wild-type fragment of the mouse APOA5 gene promoter homologous to the human RORE-DR1 in the presence of in vitro transcribed/translated ROR␣1, ROR␣2, ROR␣3, ROR␣4, and ROR␥ or unprogrammed reticulocyte lysate as control (3 L of each). DNA-protein complexes were resolved by nondenaturing PAGE. No specific complex was observed. B, The human and the other species promoter sequences homologous to the human RORE-DR1 were aligned. The sequence corresponding to the human PPRE-DR1 site AGGTTAAAGGTCA is in bold and the sequence corresponding to the human RORE half-core motif AGGTCA is underlined. Figure 3 . ROR␣1 and ROR␣4 enhance the activity of the human APOA5 gene promoter in a dose-dependent manner. A, The APOA5 promoter (Ϫ305/ϩ62) was used for the transient transfections. Exon 1 is depicted by a box with the start site of transcription indicated by ϩ1. The RORE-DR1 site (Ϫ272/Ϫ260) is in bold and the 2 mutated nucleotides are underlined. HepG2 (B) and HuH7 (C) cells were transiently cotransfected with the wild-type human APOA5 promoter fragment reporter plasmid (Ϫ305/ϩ62) cloned in front of the luciferase reporter gene (300 ng) and the pCDNA3-hROR␣1, ␣2, ␣3, ␣4, and ␥ expression plasmids (30 and 100 ng) or the empty pCDNA3 vector. HepG2 (D) and HuH7 (E) cells were transiently cotransfected with the wild-type human APOA5 promoter fragment reporter plasmid (Ϫ305/ϩ62) cloned in front of the luciferase reporter gene (300 ng) and the pCDNA3-hROR␣1 and pCDNA3-hROR␣4 expression plasmids (10, 30, 100, and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. Statistical differences from controls are indicated by asterisks (**PϽ0.01 and ***PϽ0.001). Figure 4A ) and in HuH7 cells ( Figure 4B ). These results suggest that the identified RORE-DR1 plays a key role in the regulation of the human APOA5 transcriptional activity by ROR␣. However, because 18% residual increase is still observed with the mutated construct, we cannot exclude that another mechanism independent of the binding to this site could exist. To further demonstrate that the APOA5 RORE-DR1 is functional, we cloned it in 4 tandem copies in front of an heterologous promoter and examined its response to ROR␣1 or ROR␣4 cotransfection in HepG2 and HuH7 cells. We found that this site is able to transmit ROR␣1 and ROR␣4 activator effect in a dose-dependent manner in HepG2 ( Figure 4C ) and in HuH7 cells ( Figure 4D ). Taken together, these results demonstrate that ROR␣1 and ROR␣4 increase APOA5 promoter transcriptional activity mainly by a specific binding to the RORE-DR1 at position Ϫ272/Ϫ260.
HepG2 (
Furthermore, we determined that none of the ROR␣ isoforms had any effect on the mouse promoter activity (data not shown). This is in agreement with the absence of binding in gel shift assay.
The Adenovirus-Mediated Overexpression of hROR␣1 and hROR␣4 Lead to Increase hAPOA5 mRNA Accumulation
To evaluate whether the overexpression of hROR␣1 and hROR␣4 could lead to an increase of hAPOA5 mRNA levels, HepG2 cells were infected with the Ad-ROR␣1 or the Ad-ROR␣4 adenoviral expression vector. As control, HepG2 cells were infected with the same vector, allowing expression of GFP or LacZ. Total RNA was extracted and analyzed by real-time quantitative PCR using hAPOA5-specific oligonucleotides and 36B4 as an internal control. As shown in Figure   Figure 4 . The (Ϫ305/ϩ62) region of the human APOA5 gene promoter is activated by ROR␣1 and ROR␣4 mainly via the functional RORE-DR1 present at the position (Ϫ272/Ϫ260). HepG2 (A) and HuH7 (B) cells were transiently cotransfected with the mutated APOA5 promoter fragment reporter plasmid Ϫ305/ϩ62 (Ϫ270 G3 C , Ϫ263 G3 A ) cloned in front of the luciferase reporter gene (300 ng) and the expression plasmids pCDNA3-hROR␣1, pCDNA3-hROR␣4 (100 and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. HepG2 (C) and HuH7 (D) cells were transiently cotransfected with the reporter construct containing four tandem copies of the human APOA5 RORE-DR1 inserted in front of an heterologous promoter cloned upstream of the luciferase reporter gene (300 ng) and the pCDNA3-hROR␣1 and pCDNA3-hROR␣4 expression plasmids (100 and 300 ng), or the empty pCDNA3 vector as control (300 ng) for 24 hours. Statistical differences from controls are indicated by asterisks (*PϽ0.05; **PϽ0.01 and ***PϽ0.001). 5A, an increase of hAPOA5 mRNA was observed in cells infected with the hROR␣1 adenoviral expression vector compared with control cells infected with Ad-GFP. In addition, the adenovirus-induced hAPOA5 mRNA accumulation was shown to be time-dependent to reach a 6-fold increase after 48-hour incubation. A significant increase of hAPOA5 mRNA was also observed in HepG2 cells infected with Ad-ROR␣4 compared with their control cells infected with Ad-LacZ ( Figure 5B ). These results confirm that hROR␣1 and hROR␣4 play a key role in the physiological control of APOA5 gene expression in human HepG2 cells.
Furthermore, we analyzed the hepatic apoa5 gene expression in staggerer mice, which carry a natural deletion in the ROR␣ gene ( Figure 5C ). No effect has been observed indicating that mouse apoa5 is not affected by ROR␣.
Discussion
It is well-established that hypertriglyceridemia constitutes an independent risk factor for cardiovascular diseases. 3, 4 Because APOA5 has been described as a crucial determinant of plasma triglyceride levels, 5 the identification of factors that regulate its expression is of major medical importance for the treatment of hypertriglyceridemia and associated coronary heart disease. It has been reported that hAPOA5 gene expression is upregulated by the heterodimer peroxisome proliferator-activated receptor-␣/retinoid X receptor by a direct binding to the direct repeat 1. 10, 11 Because this DR1 site presents structural homologies with the binding site for the orphan nuclear receptor ROR, we investigated the role of ROR␣ in the control of hAPOA5 gene expression. Several studies attributed an important role to ROR␣ in the regulation of lipid homeostasis by upregulating some apolipoprotein gene expression as APOA1 and APOC3 at the transcriptional level 23, 24 and recently caveolin-3 and CPT-I in skeletal muscle. 29 Moreover, it has been shown that ROR␣ has been shown to play a role in lipid homeostasis in the vascular wall. 30 Besnard et al demonstrated that ROR␣ expression is significantly decreased in human atherosclerotic plaques. 30 In addition, sg/sg mice have an increased susceptibility to atherosclerosis 25 attributed to lower high-density lipoprotein plasma levels and to heightened inflammatory response. 26 We demonstrated initially that both ROR␣1 and ROR␣4 can specifically bind to the identified RORE site Ϫ272/Ϫ260 present in the human APOA5 gene promoter, which consists of a perfect AGGTCA half-site core motif. The functional evaluation of this site, using transient cotransfection experiments with ROR␣ and wild-type or mutated RORE in the context of the hAPOA5 promoter, demonstrated that only ROR␣1 and ROR␣4 increase human APOA5 promoter activity in HepG2, as well as in HuH7 cells. In addition, in vitro experiments with Ad-ROR␣ adenoviral expression vectors revealed that ROR␣1 and ROR␣4 overexpression lead to APOA5 mRNA accumulation in HepG2 cells. Our data demonstrate that human APOA5 is a new target gene for ROR␣1 and ROR␣4. These data could strengthen the role of ROR␣ in lipid homeostasis.
The second objective of our study was to evaluate whether our results obtained in human could be extended to mouse. The sg/sg mice, which carry a natural mutation in the ROR␣ gene, exhibit an aberrant blood lipid profile associated with changes in plasma apolipoprotein levels. In particular, sg/sg mice display decreased apoC-III and triglyceride plasma levels. 25 Because the triglyceride metabolism was affected in this mouse model, we addressed the question whether apoa5 gene is involved in this mechanism. However, we show that the apoa5 gene expression is not altered in the sg/sg mice. In addition, EMSA and transient transfection experiments (data not shown) results suggested that the homologous site of human APOA5 RORE-DR1, identified at the position Ϫ272/ Ϫ260, is not functional in mice. The alignment of the human and mouse promoter sequences revealed that the mouse deviates from the human APOA5 RORE-DR1 core by 1 nucleotide and this could probably explain the nonfunctionality of this site. These data indicated that ROR␣ cannot modulate apoa5 gene expression in mice and that APOA5 is a ROR␣ target gene only in humans.
In a recent study, it was demonstrated that apoA-V and apoC-III independently influence plasma triglyceride concentrations in an opposite manner. 31 It is well-known that apoC-III, which is a component of VLDL, increases triglyceride levels via an inhibitory effect on lipoprotein lipase activity and thus constitutes a risk factor for atherosclerosis. 32 The apoC-III has been reported to be upregulated by ROR␣ and these data rather argue against the potential protective effect of ROR␣ in atherosclerosis. Interestingly, in our study, we demonstrate that ROR␣ strongly increases hAPOA5 gene expression in human hepatocytes. This new finding confers to ROR␣ a beneficial role in the regulation of triglyceride metabolism that could counteract apoC-III effect. By regulating the gene expression of both apolipoproteins, ROR␣ may play a determinant role, at least in maintaining plasma triglyceride levels in humans. In mice, a different approach may be expected because apoc3 is increased, whereas apoa5 seems to be unaffected. This hypothesis correlates with the lower circulating plasma triglyceride levels observed in sg/sg mice, which could be caused by the repression of apoc3 by the deleted ROR␣ but not by the downregulation of apoa5 in this animal model.
In conclusion, we speculate that the upregulation of hAPOA5 expression might counteract the negative effect of the upregulation of APOC3 by ROR␣ in humans and could avoid the elevation of plasma triglyceride levels. These new findings make ROR␣ a more attractive therapeutic target in the treatment of dyslipidemia and atherosclerosis.
